Robert Dunn Purchases 105,000 Shares of DIAGNOS (CVE:ADK) Stock

DIAGNOS Inc. (CVE:ADK) Director Robert Dunn acquired 105,000 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were bought at an average cost of C$0.48 per share, for a total transaction of C$50,400.00. Following the completion of the acquisition, the director directly owned 2,679,920 shares of the company’s stock, valued at approximately C$1,286,361.60. The trade was a 4.08% increase in their ownership of the stock.

Robert Dunn also recently made the following trade(s):

• On Wednesday, July 29th, Robert Dunn purchased 200,000 shares of DIAGNOS stock. The shares were purchased at an average price of C$0.30 per share, for a total transaction of C$60,000.00.

DIAGNOS Stock Performance

Shares of CVE:ADK traded up C$0.01 during trading on Friday, hitting C$0.49. The stock had a trading volume of 312,857 shares, compared to its average volume of 226,157. DIAGNOS Inc. has a 12-month low of C$0.17 and a 12-month high of C$0.52. The stock has a market capitalization of C$59.60 million, a price-to-earnings ratio of -12.38 and a beta of -0.14. The company has a quick ratio of 0.68, a current ratio of 1.49 and a debt-to-equity ratio of 204.05. The stock has a 50-day simple moving average of C$0.30 and a two-hundred day simple moving average of C$0.27.

DIAGNOS Company Profile

DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.